PASSAMONTI, FRANCESCO

PASSAMONTI, FRANCESCO  

DIPARTIMENTO DI MEDICINA E CHIRURGIA  

Mostra records
Risultati 1 - 20 di 283 (tempo di esecuzione: 0.04 secondi).
Titolo Data di pubblicazione Autore(i) File
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 1-gen-2017 Passamonti, F; Giorgino, T; Mora, B; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, J. J; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, R. T; Benevolo, G; Albano, F; Caramazza, D; Merli, M; Pietra, D; Casalone, R; Rotunno, G; Barbui, T; Cazzola, M; Vannucchi, A. M.
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 1-gen-2008 Passamonti, Francesco; Rumi, E; Caramella, M; Elena, C; Arcaini, L; Boveri, E; Del Curto, C; Pietra, D; Vanelli, L; Bernasconi, P; Pascutto, C; Cazzola, M; Morra, E; Lazzarino, M.
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 1-gen-2010 Passamonti, Francesco; Cervantes, F; Vannucchi, Am; Morra, E; Rumi, E; Pereira, A; Guglielmelli, P; Pungolino, E; Caramella, M; Maffioli, M; Pascutto, C; Lazzarino, M; Cazzola, M; Tefferi, A.
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good! 1-gen-2019 Merli, Michele; Passamonti, Francesco
A gain-of-function mutation of JAK2 in myeloproliferative disorders 1-gen-2005 Kralovics, R; Passamonti, Francesco; Buser, As; Teo, Ss; Tiedt, R; Passweg, Jr; Tichelli, A; Cazzola, M; Skoda, Rc
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients 1-gen-2007 Brazzelli, V; Prestinari, F; Barbagallo, T; Rona, C; Orlandi, E; Passamonti, Francesco; Locatelli, F; Zecca, M; Villani, S; Borroni, G.
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion 1-gen-2017 Pessina, Chiara; Basilico, Claudia; Genoni, Angelo; Meroni, Emanuela; Elli, Lorenzo; Granata, Paola; Righi, Rossana; Pallotti, Francesco; Mora, Barbara; Ferrario, Andrea; Passamonti, Francesco; Casalone, Rosario
A novel germline JAK2 mutation in familial myeloproliferative neoplasms 1-gen-2014 Rumi, E.; Harutyunyan, A. S.; Casetti, I.; Pietra, D.; Nivarthi, H.; Moriggl, R.; Cleary, C.; Bagienski, K.; Astori, C.; Bellini, M.; Berg, T.; Passamonti, Francesco; Kralovics, R.; Cazzola, M.
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 1-gen-2014 Verstovsek, S.; Passamonti, Francesco; Rambaldi, A.; Barosi, G.; Rosen, P. J.; Rumi, E.; Gattoni, E.; Pieri, L.; Guglielmelli, P.; Elena, C.; He, S.; Contel, N.; Mookerjee, B.; Sandor, V.; Cazzola, M.; Kantarjian, H. M.; Barbui, T.; Vannucchi, A. M.
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis 1-gen-2018 Couban, Stephen; Benevolo, Giulia; Donnellan, William; Cultrera, Jennifer; Koschmieder, Steffen; Verstovsek, Srdan; Hooper, Gregory; Hertig, Christian; Tandon, Maneesh; Dimier, Natalie; Malhi, Vikram; Passamonti, Francesco
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis 1-gen-2015 Vannucchi, Alessandro M; Kantarjian, Hagop M.; Kiladjian, Jean Jacques; Gotlib, Jason; Cervantes, Francisco; Mesa, Ruben A.; Sarlis, Nicholas J.; Peng, Wei; Sandor, Victor; Gopalakrishna, Prashanth; Hmissi, Abdel; Stalbovskaya, Viktoriya; Gupta, Vikas; Harrison, Claire; Verstovsek, Srdan; Passamonti, Francesco
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 1-gen-2022 Visco, C.; Marcheselli, L.; Mina, R.; Sassone, M.; Guidetti, A.; Penna, D.; Cattaneo, C.; Bonuomo, V.; Busca, A.; Ferreri, A. J. M.; Bruna, R.; Petrucci, L.; Cairoli, R.; Salvini, M.; Bertu, L.; Ladetto, M.; Pilerci, S.; Pinto, A.; Ramadan, S.; Marchesi, F.; Cavo, M.; Arcaini, L.; Coviello, E.; Romano, A.; Musto, P.; Massaia, M.; Fracchiolla, N.; Marchetti, M.; Scattolin, A.; Tisi, M. C.; Cuneo, A.; Porta, M. D.; Trentin, L.; Turrini, M.; Gherlinzoni, F.; Tafuri, A.; Galimberti, S.; Bocchia, M.; Cardinali, V.; Cilloni, D.; Corso, A.; Armiento, D.; Rigacci, L.; La Barbera, E. O.; Gambacorti-Passerini, C.; Visani, G.; Vallisa, D.; Venditti, A.; Selleri, C.; Conconi, A.; Tosi, P.; Lanza, F.; Candoni, A.; Krampera, M.; Corradini, P.; Passamonti, F.; Merli, F.
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 1-gen-2022 Maffioli, M.; Mora, B.; Ball, S.; Iurlo, A.; Elli, E. M.; Finazzi, M. C.; Polverelli, N.; Rumi, E.; Caramella, M.; Carraro, M. C.; D'Adda, M.; Molteni, A.; Sissa, C.; Lunghi, F.; Vismara, A.; Ubezio, M.; Guidetti, A.; Caberlon, S.; Anghilieri, M.; Komrokji, R.; Cattaneo, D.; Della Porta, M. G.; Giorgino, T.; Bertu, L.; Brociner, M.; Kuykendall, A.; Passamonti, F.
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. 1-gen-2012 Passamonti, Francesco; Thiele, J; Girodon, F; Rumi, E; Carobbio, A; Gisslinger, H; Kvasnicka, Hm; Ruggeri, M; Randi, Ml; Gangat, N; Vannucchi, Am; Gianatti, A; Gisslinger, B; Müllauer, L; Rodeghiero, F; D'Amore, Es; Bertozzi, I; Hanson, Ca; Boveri, E; Marino, F; Maffioli, M; Caramazza, D; Antonioli, E; Carrai, V; Buxhofer Ausch, V; Pascutto, C; Cazzola, M; Barbui, T; Tefferi, A.
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 1-gen-2010 Passamonti, Francesco; Rumi, E; Pietra, D; Elena, C; Boveri, E; Arcaini, L; Roncoroni, E; Astori, C; Merli, M; Boggi, S; Pascutto, C; Lazzarino, M; Cazzola, M.
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence 1-gen-2017 Tefferi, A; Al Ali, H. K; Barosi, G; Devos, T; Gisslinger, H; Jiang, Q; Kiladjian, J. J; Mesa, R; Passamonti, Francesco; Mcmullin, M. F; Ribrag, V; Schiller, G; Vannucchi, A. M; Zhou, D; Reiser, D; Zhong, ; R. P. Gale for the RESUME trialists, J.
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process 1-gen-2009 Barosi, G; Birgegard, G; Finazzi, G; Griesshammer, M; Harrison, C; Hasselbalch, H; Kiladijan, Jj; Lengfelder, E; Mesa, R; Mc Mullin, Mf; Passamonti, Francesco; Reilly, Jt; Vannucchi, Am; Barbui, T.
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 1-gen-2013 Rumi, E.; Pietra, D.; Guglielmelli, P.; Bordoni, R.; Casetti, I.; Milanesi, C.; Sant’Antonio, E.; Ferretti, V.; Pancrazzi, A.; Rotunno, G.; Severgnini, M.; Pietrelli, A.; Astori, C.; Fugazza, E.; Pascutto, C.; Boveri, E.; Passamonti, Francesco; De Bellis, G.; Vannucchi, A.; Cazzola, M.
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA 1-gen-2002 Bernasconi, P.; Boni, M.; Cavigliano, P. M. .; Calatroni, S.; Brusamolino, E.; Passamonti, Francesco; Pistorio, A.; Giardini, I.; Rocca, B.; Caresana, M.; Lazzarino, M.; Brernasconi, C.
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) 1-gen-2022 Guglielmelli, P.; Palandri, F.; Selleri, C.; Cilloni, D.; Mendicino, F.; Mazza, P.; Pastore, D.; Palumbo, G. A.; Santoro, M.; Pavone, V.; Impera, S.; Morelli, M.; Coco, P.; Valsecchi, D.; Passamonti, F.; Breccia, M.